We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,183

China’s NHFPC further strengthening its scrutiny over irregularities in the healthcare industry
  • King & Wood Mallesons
  • China
  • March 18 2014

China's National Health and Family Planning Commission(" NHFPC ") has recently stepped up its efforts to strengthen the administration of healthcare


CFDA’s New Draft Policy Introduces the Chinese Version of Patent Linkage
  • Allen & Overy LLP
  • China
  • May 16 2017

On May 12, Chinese Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and


China issues implementation rules for its new pharmaceutical and medical device blacklist system
  • Sidley Austin LLP
  • China
  • March 19 2014

On December 27, 2013, China's National Health and Family Planning Commission (NHFPC) published an agency rule to update the "blacklist system" for


China cracking down on pharmaceutical corruption
  • Sheppard Mullin Richter & Hampton LLP
  • China, USA
  • March 25 2014

On December 25, 2013, the National Health and Family Planning Commission of China ("National Health Commission", former Ministry of Health) issued


Updated rules on registration of medical devices more stringent requirements for foreign medical device companies
  • CMS, China
  • China
  • October 20 2014

As a consequence of the introduction of the new Regulation on the Supervision and Administration of Medical Devices ("New Regulation"), effective


Medical devices: new rules and uncertainties
  • CMS Cameron McKenna
  • China
  • June 9 2014

The revised "Regulation on the Supervision and Administration of Medical Devices"(hereinafter referred to as the "New Regulation") (enacted by the


CFDA seeks public comment on Special Approval Procedures for Innovative Medical Devices
  • Reed Smith LLP
  • China
  • April 26 2013

China Food and Drug Administration ("CFDA," previously known as "SFDA") issued a draft Notice on Soliciting Public Comments on the Special Approval


SFDA 2012 Anual Drug Review Report highlights innovator focus
  • Sidley Austin LLP
  • China
  • March 8 2013

On February 28, 2013, the Center for Drug Evaluation of the State Foodand Drug Administration ("CDE"), the key agency reviewing safety andefficacy


New circular on Chinese generic pharmaceutical manufacturers: greater leeway and new opportunities
  • CMS, China
  • China
  • March 14 2013

Non-Chinese companies seem to have new opportunities to acquire Chinese generic pharmaceutical manufacturers through transfer of technology thanks to


Groundbreaking establishment of the first wholly foreign invested hospital project in China (Shanghai) Pilot Free Trade Zone
  • CMS, China
  • China
  • August 21 2014

On 22 July 2014, a framework agreement relating to the establishment of the first wholly foreign invested hospital in China (Shanghai) Pilot Free